“pH Pharma's vision is focused on developing
innovative healthcare products for ​unmet
clinical and consumer needs”

Dr. Hoyoung Huh ​Founder of pH Pharma September 28, 2015



“pH Pharma's vision is focused on developing innovative healthcare products for ​unmet clinical and consumer needs

Dr. Hoyoung Huh​ Founder of pH Pharma September 28, 2015

pH Pharma is a biopharmaceutical company with expertise in developing innovative products in multiple therapeutic areas.
With presence in Seoul and Silicon Valley, we create an innovative healthcare platform by bridging unique talents and assets across different cultures and backgrounds.
Each day, we bring to work our passion to develop sustainable drug treatments and contribute to improving human health and quality of life around the globe.



Our corporate strategy is based on pH Pharma’s “3P’s” principle

Identify and penetrate growing markets with innovative treatments
Develop Best-In-Class / First-In-Class novel therapeutic agents
Capitalize on global network and biotech hub
Build optimum platform to effectively capture new opportunities
Assemble a global team to effectively utilize know-how and frontier technologies
Develop future global leaders in the biopharmaceutical industry


  • PHP-201 (Glaucoma)
  • PHP-303 (NASH, Genetic Diseases)
  • Torpedo (Oncology)
  • Corporate
  • Diabetes
  • 2019

    • ‘19.05ASIA Research Center Open(Pangyo Valley)
    • ‘19.03Bridge Funding complete (KR)
    • ‘19.03PHP-201 APAO(ASIA-Pacific Academy of Ophthalmology) Phase 2b result presented
    • ‘19.01PHP-303 Phase 1b (MAD) initiated(US)
  • 2018

    • ‘18.12PHP-303 Phase 1b (SAD) initiated(US)
    • ‘18.12PHP-201 Phase 2b CSR(Clinical Study Report) completed
    • ‘18.08PHP-303 Phase Ib initiated(US)
    • ‘18.06PHP-201 Phase IIb study complete (KR)
    • ‘18.04Global Research Center Open(Silicon Valley)
    • ‘18.03Investment & research collaboration with Pliant Therapeutics
    • ‘18.01Series B funding (tranche 4) complete
  • 2017

    • ‘17.11Toxins in-licensed from Purdue University
    • ‘17.04Series B funding (tranche 3) complete
    • ‘17.02PHP-201 Phase IIb study initiated
    • ‘17.02PHP-303 (former “BAY85-8501”) acquired from Bayer
  • 2016

    • ‘16.12Series B funding (tranche 1, 2) complete
    • ‘16.10PHP-201 Phase IIb study IND approved
    • ‘16.04Series A funding complete
    • ‘16.03AB101 in-licensed from from Rezolute (former “AntriaBio”)
    • ‘16.02pH Pharma Inc. established (US subsidiary of pH Pharma Co., Ltd.)
    • ‘16.02PHP-201 (former “AMA0076”) in-licensed from Amakem Therapeutics
  • 2015

    • ‘15.09pH Pharma Co., Ltd. established